Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 12/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | PHGDH | O43175 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485945 | 1.00 | RORC (0.53) | RORCLMNAROCK2ROCK1PHGDH | |
| SCHEMBL30065071 | 0.85 | RORC (0.56) | RORCROCK2ROCK1PHGDHKMT2A | |
| SCHEMBL23632705 | 0.85 | RORC (0.56) | RORCROCK2ROCK1PHGDHKMT2A | |
| SCHEMBL23632706 | 0.85 | RORC (0.56) | RORCROCK2ROCK1PHGDHKMT2A | |
| SCHEMBL30065065 | 0.84 | RORC (0.56) | RORCROCK2ROCK1 | |
| SCHEMBL30065079 | 0.84 | RORC (0.51) | RORCPHGDH | |
| SCHEMBL30485940 | 0.84 | RORC (0.55) | RORCLMNAROCK2ROCK1 | |
| SCHEMBL30065092 | 0.80 | KAT6A (0.50) | RORCLMNAPHGDHKMT2AALDH1A1 | |
| SCHEMBL28708836 | 0.79 | RORC (0.55) | RORCROCK2ROCK1 | |
| SCHEMBL28708837 | 0.79 | RORC (0.55) | RORCROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113912597-B | ROR gamma inhibitor, preparation method and medical application thereof | 赛诺哈勃药业（成都）有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | RORC 1/4885LMNA 3290/4885ROCK2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.